NS1 DNA vaccination protects against Zika infection through T cell–mediated immunity in immunocompetent mice

B. Grubor-Bauk, D. K. Wijesundara, M. Masavuli, P. Abbink, R. L. Peterson, N. A. Prow, R. A. Larocca, Z. A. Mekonnen, A. Shrestha, N. S. Eyre, M. R. Beard, J. Gummow, J. Carr, S. A. Robertson, J. D. Hayball, D. H. Barouch, E. J. Gowans

    Research output: Contribution to journalArticlepeer-review

    6 Citations (Scopus)
    4 Downloads (Pure)

    Abstract

    The causal association of Zika virus (ZIKV) with microcephaly, congenital malformations in infants, and Guillain-Barré syndrome in adults highlights the need for effective vaccines. Thus far, efforts to develop ZIKV vaccines have focused on the viral envelope. ZIKV NS1 as a vaccine immunogen has not been fully explored, although it can circumvent the risk of antibody-dependent enhancement of ZIKV infection, associated with envelope antibodies. Here, we describe a novel DNA vaccine encoding a secreted ZIKV NS1, that confers rapid protection from systemic ZIKV infection in immunocompetent mice. We identify novel NS1 T cell epitopes in vivo and show that functional NS1-specific T cell responses are critical for protection against ZIKV infection. We demonstrate that vaccine-induced anti-NS1 antibodies fail to confer protection in the absence of a functional T cell response. This highlights the importance of using NS1 as a target for T cell–based ZIKV vaccines.

    Original languageEnglish
    Article numbereaax2388
    Number of pages16
    JournalScience Advances
    Volume5
    Issue number12
    DOIs
    Publication statusPublished - 11 Dec 2019

    Fingerprint Dive into the research topics of 'NS1 DNA vaccination protects against Zika infection through T cell–mediated immunity in immunocompetent mice'. Together they form a unique fingerprint.

    Cite this